search
Back to results

Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis

Primary Purpose

Appendicitis, Appendicitis; Perforation

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Lactobacillus rhamnosus GG (LGG) Probiotic
Placebo
Sponsored by
Children's Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Appendicitis focused on measuring Appendicitis, Probiotics

Eligibility Criteria

4 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with a post-operative diagnosis of complicated appendicitis who undergo an immediate appendectomy.
  2. Patients between the ages of 4 and 18 years of age.

Exclusion Criteria:

  1. Patients diagnosed with an complicated appendicitis with deferred appendectomy or non-perforated appendicitis
  2. Patients that have a history of being immunosuppressed, on immunosuppression therapy, or long-term steroid therapy within the last month.
  3. Patients that have central line access.
  4. Patients under 4 years of age.
  5. Patients that are developmentally delayed and cannot ambulate at baseline.
  6. Patients with significant past medical history.
  7. Patients that are in Child Protective Services custody.
  8. Patients that are incarcerated.
  9. Patients that are pregnant.
  10. Patients that speak languages other than English and Spanish.

Sites / Locations

  • Children's Health Children's Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Lactobacillus rhanmosus GG(LGG®) Group

Placebo Control Group

Arm Description

Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health. As such, this dietary supplement is not reviewed and approved by the FDA. This study does not intend to investigate route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the dietary supplement. Patients in the treatment group will receive a standard dose of Lactobacillus rhamnosus GG capsule following their surgery while in the hospital until discharge.

Patients in the placebo group will receive a placebo capsule following their surgery while in the hospital until discharge.

Outcomes

Primary Outcome Measures

Length of Hospital Stay
Length of hospital stay measured in hours from admission to discharge.

Secondary Outcome Measures

Number of diarrhea episodes daily
Documented number of diarrhea episodes each day in EHR.
Number of times patient ambulated each day
Documented number of times patient ambulated each day in EHR.

Full Information

First Posted
August 24, 2020
Last Updated
June 13, 2022
Sponsor
Children's Health
search

1. Study Identification

Unique Protocol Identification Number
NCT04529980
Brief Title
Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis
Official Title
Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis: Prospective Controlled-Comparison Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
September 8, 2020 (Actual)
Primary Completion Date
February 28, 2022 (Actual)
Study Completion Date
February 28, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Children's Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To determine the effectiveness of the use of probiotics in patients with a diagnosis of complicated appendicitis on antibiotic associated diarrhea (AAD). Probiotics are defined as live microbial organisms that when administered in sufficient amounts, can provide a protective benefit to the individual patient. The use of probiotics in a pediatric population exposed to antibiotics and gastrointestinal surgery such as an appendectomy may provide a protective effect and prevent antibiotic associated diarrhea (ADD)
Detailed Description
Appendicitis is the most common urgent surgical procedure performed on children. Approximately one third of the population end up having complicated appendicitis with evidence of peritoneal contamination and infection or abscess requiring the use of IV antibiotics and prolonged hospital stay. Antibiotic Associated Diarrhea (AAD) is a common complication seen in both outpatient and inpatient settings in approximately a third of all patients treated with antibiotics (Mantegazza, et al., 2018). In particular, pediatric patients experience ADD 11-62% of the time and can up upwards to 80% in hospitalized toddlers (Mantegazza, et al., 2018). Current literature defines AAD as three or more liquid stools per day. The causes of AAD are often related to the use of multiple antibiotics, prolonged hospital stay and gastrointestinal surgery. Antibiotics often disturb the normal enteric microbiome in the gut and allow for an increased growth of pathogens (Hojsak, 2017). AAD can occur as late as six to eight weeks after antibiotic exposure. Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.This study does not intend to investigate route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the dietary supplement.At Children's Medical Center, the investigators see over 1000 cases of appendicitis a year with approximately 1/3 of those patients being complicated appendicitis. For those requiring immediate appendectomy, the typical course of treatment include surgery, admission to the hospital for 3 to 5 days, administration of IV antibiotics while in hospital, and discharge orders for oral antibiotics to complete their treatment. The investigators propose to perform a randomized controlled trial where one group of patients will receive probiotic therapy and another group of patients does not. The investigators hypothesize patients given probiotics after a diagnosis of complicated appendicitis with immediate appendectomy who receive antibiotic treatment during their inpatient stay will decrease the overall length of stay (LOS) by 25% vs the LOS in those patients who do not receive probiotics.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Appendicitis, Appendicitis; Perforation
Keywords
Appendicitis, Probiotics

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Those randomized to the treatment group will be given probiotic therapy until discharge, while those randomized to the placebo group will be given a placebo until discharge.
Masking
ParticipantCare Provider
Masking Description
Patients will be randomized into two study groups using randomization and utilizing a sealed envelope randomization plan. Both the care providers and study participants (parents/LAR) will be masked from which treatment assignment the participant was randomized to.
Allocation
Randomized
Enrollment
98 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lactobacillus rhanmosus GG(LGG®) Group
Arm Type
Experimental
Arm Description
Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health. As such, this dietary supplement is not reviewed and approved by the FDA. This study does not intend to investigate route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the dietary supplement. Patients in the treatment group will receive a standard dose of Lactobacillus rhamnosus GG capsule following their surgery while in the hospital until discharge.
Arm Title
Placebo Control Group
Arm Type
Placebo Comparator
Arm Description
Patients in the placebo group will receive a placebo capsule following their surgery while in the hospital until discharge.
Intervention Type
Dietary Supplement
Intervention Name(s)
Lactobacillus rhamnosus GG (LGG) Probiotic
Other Intervention Name(s)
Culturelle Probiotics Digestive Health
Intervention Description
Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Length of Hospital Stay
Description
Length of hospital stay measured in hours from admission to discharge.
Time Frame
Through study completion, an average 1 year
Secondary Outcome Measure Information:
Title
Number of diarrhea episodes daily
Description
Documented number of diarrhea episodes each day in EHR.
Time Frame
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Title
Number of times patient ambulated each day
Description
Documented number of times patient ambulated each day in EHR.
Time Frame
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with a post-operative diagnosis of complicated appendicitis who undergo an immediate appendectomy. Patients between the ages of 4 and 18 years of age. Exclusion Criteria: Patients diagnosed with an complicated appendicitis with deferred appendectomy or non-perforated appendicitis Patients that have a history of being immunosuppressed, on immunosuppression therapy, or long-term steroid therapy within the last month. Patients that have central line access. Patients under 4 years of age. Patients that are developmentally delayed and cannot ambulate at baseline. Patients with significant past medical history. Patients that are in Child Protective Services custody. Patients that are incarcerated. Patients that are pregnant. Patients that speak languages other than English and Spanish.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mayra Garcia, APRN, CNS
Organizational Affiliation
Children's Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Health Children's Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75235
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30078376
Citation
Agamennone V, Krul CAM, Rijkers G, Kort R. A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands. BMC Gastroenterol. 2018 Aug 6;18(1):103. doi: 10.1186/s12876-018-0831-x.
Results Reference
background
PubMed Identifier
31377301
Citation
Bethel M. Probiotics for the prevention of pediatric antibiotic-associated diarrhea: Summary of a Cochrane review. Explore (NY). 2019 Sep-Oct;15(5):382-383. doi: 10.1016/j.explore.2019.07.001. Epub 2019 Jul 11. No abstract available.
Results Reference
background
PubMed Identifier
27688016
Citation
Hayes SR, Vargas AJ. Probiotics for the Prevention of Pediatric Antibiotic-Associated Diarrhea. Explore (NY). 2016 Nov-Dec;12(6):463-466. doi: 10.1016/j.explore.2016.08.015. Epub 2016 Aug 26.
Results Reference
background
PubMed Identifier
29026729
Citation
Hojsak I. Probiotics in Children: What Is the Evidence? Pediatr Gastroenterol Hepatol Nutr. 2017 Sep;20(3):139-146. doi: 10.5223/pghn.2017.20.3.139. Epub 2017 Sep 26.
Results Reference
background
PubMed Identifier
28827186
Citation
Mantegazza C, Molinari P, D'Auria E, Sonnino M, Morelli L, Zuccotti GV. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Pharmacol Res. 2018 Feb;128:63-72. doi: 10.1016/j.phrs.2017.08.001. Epub 2017 Aug 19.
Results Reference
background
PubMed Identifier
26365389
Citation
Szajewska H, Kolodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015 Nov;42(10):1149-57. doi: 10.1111/apt.13404. Epub 2015 Sep 13.
Results Reference
background
Links:
URL
https://doi.org/10.1016/j.pepo.2013.12.003
Description
Wanke, M. & Szajewska, H. (2014). Probiotics for preventing healthcare-associated diarrhea in

Learn more about this trial

Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis

We'll reach out to this number within 24 hrs